Bumetanide is a loop diuretic that inhibits the Na⁺-K⁺-2Cl⁻ cotransporter 1 (NKCC1), a chloride importer expressed throughout the central nervous system. By reducing intracellular chloride, bumetanide restores the inhibitory function of GABA_A receptors in mature neurons, effectively reducing neuronal hyperexcitability. This mechanism has led to exploration of bumetanide as a repurposed therapy for Alzheimer's disease, where network hyperexcitability and epileptiform activity are increasingly recognized as key features.
NKCC1 (encoded by SLC12A2) imports Na⁺, K⁺, and Cl⁻ into neurons, maintaining elevated intracellular chloride levels. In mature neurons, this prevents GABA_A receptor activation from hyperpolarizing the cell, as the chloride reversal potential is more positive than the resting membrane potential. This developmental shift from depolarizing to hyperpolarizing GABA is mediated by the K⁺-Cl⁻ cotransporter KCC2.
In Alzheimer's disease, several mechanisms upregulate NKCC1 activity and impair KCC2 function:
The result is increased neuronal excitability, network dysrhythmia, and heightened seizure susceptibility in AD patients[1].
Bumetanide inhibits NKCC1, reducing intracellular chloride and restoring GABA_A-mediated inhibition:
A key limitation of bumetanide for CNS applications is its poor blood-brain barrier penetration. Standard doses achieve limited CNS concentrations. Strategies being explored include:
A Phase 2 clinical trial (NCT06052163) is evaluating bumetanide in early Alzheimer's disease:
This represents the first systematic evaluation of NKCC1 inhibition in a registrational-quality AD trial.
Multiple preclinical studies support bumetanide's potential in AD:
AD patients show elevated rates of:
Approximately 10-20% of AD patients have comorbid epilepsy. Treating seizures with bumetanide may provide dual benefit:
Tavassoly O, et al. NKCC1 involvement in Alzheimer's disease: from physiology to pathology. J Alzheimers Dis. 2021. ↩︎
Holper S, et al. Bumetanide improves synaptic plasticity and memory deficits in APP/PS1 mice. J Alzheimers Dis. 2019. ↩︎